Amsterdam-based healthcare technology company BioIntelliSense has announced a new partnership that will see healthcare technology company Royal Philips integrate its BioSticker biometric monitoring solution with Philips’ remote patient monitoring (RPM) offering.
The BioSticker — which is single use and has received FDA clearance — contains biometric sensors that provide continuous monitoring of the wearer’s vital signs, and provides actionable insights for clinical analysis.
Capable of providing valuable data on factors such as skin temperature, resting heart rate, resting respiratory rate, body position, activity levels, and cough frequency, the BioSticker allows the Philips’ RPM solution to provide clinicians with more data for people living with chronic conditions without requiring them to visit a hospital or healthcare facility.
RPM and telehealth solutions are growing in popularity in light of the COVID-19 pandemic, as they allow for the tracking of a patient’s symptoms from their home, which helps to keep hospitals focused on treating individuals who require hospitalization.
“With more patients interacting with their doctors from home and more hospitals developing strategies to virtually engage with their patients, remote patient monitoring is now, more than ever, an essential tool,” said Roy Jakobs, a member of the Executive Committee at Royal Philips. “Building on Philips’ global leadership in patient monitoring… this is the latest example of our capability to allow more seamless, cloud-based data collection across multiple settings from the home to the hospital and back into the home.”
Jakobs goes on to note that Philips’ artificial intelligence-powered technology works in concert with the biometric data collected from the BioSticker to create “relevant actionable insights to help detect deterioration trends and support care interventions – all while outside the walls of the hospital.”
“Multi-parameter sensors are the natural next phase for remote monitoring, especially at a time when more patients are engaging with their physicians from home,” said James Mault, MD, Founder and Chief Executive Officer of BioIntelliSense. “Philips is a demonstrated leader in remote patient monitoring, and we look forward to BioIntelliSense’s technology playing an integral role in simplifying and enhancing outcomes for patients and their doctors.”
The first company to leverage Philips’ new RPM solution in the U.S is health plan provider Healthcare Highways, which will deploy it across seven programs, one of which will be specifically focused on monitoring patients who have COVID-19.